Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Sep 23;11(9):e1001735.
doi: 10.1371/journal.pmed.1001735. eCollection 2014 Sep.

Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial

Raquel González  1 , Meghna Desai  2 , Eusebio Macete  3 , Peter Ouma  4 , Mwaka A Kakolwa  5 , Salim Abdulla  5 , John J Aponte  1 , Helder Bulo  3 , Abdunoor M Kabanywanyi  5 , Abraham Katana  4 , Sonia Maculuve  3 , Alfredo Mayor  1 , Arsenio Nhacolo  3 , Kephas Otieno  4 , Golbahar Pahlavan  6 , María Rupérez  1 , Esperança Sevene  3 , Laurence Slutsker  7 , Anifa Vala  3 , John Williamsom  2 , Clara Menéndez  1
Affiliations
Randomized Controlled Trial

Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial

Raquel González et al. PLoS Med. .

Abstract

Background: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention in HIV-negative pregnant women, but it is contraindicated in HIV-infected women taking daily cotrimoxazole prophylaxis (CTXp) because of potential added risk of adverse effects associated with taking two antifolate drugs simultaneously. We studied the safety and efficacy of mefloquine (MQ) in women receiving CTXp and long-lasting insecticide treated nets (LLITNs).

Methods and findings: A total of 1,071 HIV-infected women from Kenya, Mozambique, and Tanzania were randomized to receive either three doses of IPTp-MQ (15 mg/kg) or placebo given at least one month apart; all received CTXp and a LLITN. IPTp-MQ was associated with reduced rates of maternal parasitemia (risk ratio [RR], 0.47 [95% CI 0.27-0.82]; p=0.008), placental malaria (RR, 0.52 [95% CI 0.29-0.90]; p=0.021), and reduced incidence of non-obstetric hospital admissions (RR, 0.59 [95% CI 0.37-0.95]; p=0.031) in the intention to treat (ITT) analysis. There were no differences in the prevalence of adverse pregnancy outcomes between groups. Drug tolerability was poorer in the MQ group compared to the control group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ administration). HIV viral load at delivery was higher in the MQ group compared to the control group (p=0.048) in the ATP analysis. The frequency of perinatal mother to child transmission of HIV was increased in women who received MQ (RR, 1.95 [95% CI 1.14-3.33]; p=0.015). The main limitation of the latter finding relates to the exploratory nature of this part of the analysis.

Conclusions: An effective antimalarial added to CTXp and LLITNs in HIV-infected pregnant women can improve malaria prevention, as well as maternal health through reduction in hospital admissions. However, MQ was not well tolerated, limiting its potential for IPTp and indicating the need to find alternatives with better tolerability to reduce malaria in this particularly vulnerable group. MQ was associated with an increased risk of mother to child transmission of HIV, which warrants a better understanding of the pharmacological interactions between antimalarials and antiretroviral drugs.

Trial registration: ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001813440 Please see later in the article for the Editors' Summary.

Trial registration: ClinicalTrials.gov NCT00811421.

PubMed Disclaimer

Conflict of interest statement

CM is a member of the Editorial Board of PLOS Medicine. The rest of coauthors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Trial profile (ITT cohort).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gonzalez R, Ataide R, Naniche D, Menendez C, Mayor A (2012) HIV and malaria interactions: where do we stand? Expert Rev Anti Infect Ther 10: 153–165. - PubMed
    1. ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, et al. (2004) The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 71: 41–54. - PubMed
    1. Uneke CJ, Ogbonna A (2009) Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents. Trans R Soc Trop Med Hyg 103: 761–767. - PubMed
    1. van Eijk AM, Ayisi JG, ter Kuile FO, Misore AO, Otieno JA, et al. (2003) HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS 17: 595–603. - PubMed
    1. Mayor A, Kumar U, Bardaji A, Gupta P, Jimenez A, et al. (2013) Improved pregnancy outcomes in women exposed to malaria with high antibody levels against Plasmodium falciparum. J Infect Dis 207: 1664–1674. - PubMed

Publication types

MeSH terms

Substances

Associated data